After a week of being too close to call, Californias Proposition 14 has passed, allowing the state to issue $5.5 billion in bonds for stem cell research.
The measure flew under the radar early in the election season, with almost no opposition and $15 million spent by proponents. But Californians were split on the measure, with just 51% of residents voting yes as of Nov. 12 when the race was called.
Proposition 14 was brought forward by real estate developer Robert Klein, who formerly served as board chairman of the California Institute for Regenerative Medicine (CIRM). The agency was created by another ballot proposition in 2004, and remains one of the only state-funded stem cell research agencies in the United States.
John Matsusaka, a University of Southern California economist with a focus on the ballot process, says this measure put a tough decision on voters.
Theres many useful things you might want to do research on, is this the one you want to put so much money into, he asked. This was an interest group who said they wanted to carve out one thing for themselves which raises some questions.
CIRM was envisioned as a mecca of biological discovery that would make California a leader in curing diseases such as Alzheimers, cancer and diabetes. Proponents say a new injection of state funding will help them continue this important work.
But the agency has faced criticism over the years from those who feel the promised research hasnt materialized, and that conflicts of interest have compromised the institutes integrity.
David Jensen, author of a book about the Institute called Californias Great Stem Cell Experiment, says even with the passage of Proposition 14, doubts about the agencys future remain.
[In 2004], people were led to believe that stem cell therapies and cures were right around the corner. That did not turn out to be the case, he said. It's very important to finance stem cell research. The question is, should the state do that?
Controversial Beginnings
California voters were first asked to weigh in on stem cell funding in 2004. At the time, George W. Bush was in the White House and had banned federally funded embryonic stem cell research.
That meant California scientists investigating HIV/AIDS treatments, Parkinson's cures and more were fighting over a trickling well of funding. So they took to the ballot with Proposition 71, which passed with 59% of the votes. That allowed the state to issue $3 billion in bonds for the creation of the California Institute for Regenerative Medicine.
Because of the timing, it was a shot in the arm to the field, said Zach Hall, who served as the first president of CIRM.
Proposition 14 opponents argue that because former President Barack Obama lifted restrictions on embryonic stem cell research, California scientists can now lean on federal grants and private industry funding to carry their work through.
The NIH could support most of the work that CIRM has funded in the past 10 years, and so the rationale for having a new proposition and increasing the amount of money is unclear, Hall said. You could say just as well why dont we have a state agency to fund CRISPR research?
But supporters argue that federal grants are competitive, and there isnt enough money in the national cache or in private industry to backfill what CIRM provides for researchers across the state.
Robert Klein, former chairman of the Institutes board and leader of the campaign supporting Proposition 14, said that without new bond funding, the Institutes existing research projects would be out of money once they reach the ends of their current grant cycles.
Those trials will not have any funding available to take them forward, he said. And we have a pent-up demand waiting for these new funds from Prop 14 for dozens of new trials for new therapies.
Last summer CIRM told researchers it would stop accepting new grant applications, with the exception of $5 million in emergency funding it set aside for COVID-19 research.
Where Did The First $3 Billion Go?
Supporters of Proposition 14 say the work that CIRM has done over the years has brought California to the forefront in stem cell research, and laid the groundwork for cures to hundreds of diseases.
The agency has distributed hundreds of research grants to public and private universities, medical research institutions and for-profit companies.
Nearly 40%of that money has gone into basic research that helps scientists understand stem cells and how they might be used in medicine, according to a San Francisco Chronicle analysis of CIRM spending. The list of conditions researchers have focused on is long, and includes heart disease, Huntingtons, leukemia, Alzheimers and glioblastoma, to name just a few.
CIRM put 16% of the money into building infrastructure, including about a dozen stem cell research centers, according to the analysis. Another $388 million went toward taking research out of the lab and applying it to humans.
Of the 90 clinical trials the Institute has funded, two drugs have earned FDA approval for fatal forms of blood cancer, according to the campaign supporting the proposition.
The campaign reports CIRM-funded researchers have published 2,900 medical discoveries.
From Sacramento to San Francisco to LA to San Diego, these world eminent scientist leaders in this field came together and said we have to have this funding to go forward, Klein said. We cant attract and hold the best scientists in the world unless we can show them that the therapies they work on are going to actually be able to get to patients.
Supporters also argue that Proposition 71 was an economic boon for the Golden State. A 2019 study from the University of Southern California (commissioned by CIRM) estimates that the Institutes impact on Californias economy is $10.7 billion in gross output, $641.3 million in tax revenue and nearly 56,000 jobs created.
But Matsusaka, a USC economics professor who was not affiliated with that study, says hes doubtful that the $5.5 billion that Proposition 14 will inject into stem cell research will be the job-generator California needs now.
This is money thats channeling into research, into scientists, into highly skilled white collar workers who are very fully employed already, he said. If you were pouring money into restaurant workers or something like that I think there could be a stimulating effect because thats where theres a big pool of people who are unemployed right now. Its hard for me to see how pouring money into this could have a stimulating effect.
And he says pulling money out of other sectors to support this work could do harm to the states economy more broadly.
Conflicts of Interest
At several points during its 16-year history, CIRM has been criticized for conflicts of interest between its board and the researchers it supports.
An analysis from the California Stem Cell Report, which has been tracking the agency since its inception, found that Stanford University, UCLA and UC San Diego are the top recipients of CIRM funding, and they all have representatives on the CIRM board.
Far too many board members represent organizations that receive CIRM funding or benefit from that funding, wrote the National Academy of Medicine in a 2012 study of the agency. These competing personal and professional interests compromise the perceived independence of the ICOC (the CIRM governing board), introduce potential bias into the boards decision making, and threaten to undermine confidence in the board.
In 2014, a former CIRM president left his job and almost immediately took a high-paying position at an agency that receives research funding from the Institute. David Jensen with California Stem Cell Report has tracked several other conflict of interest issues within the organization.
He says Proposition 14 changes some legal definitions and increases the number of people on the board from 29 to 35, but does not do anything to ameliorate those problems.
If youve got the dean of the medical school at UC Davis sitting on that board, voting on programs that might benefit his or her institution, legally or not thats still a conflict of interest, he said.
The agency has historically argued that the relationships between its board members and the scientists it supports are in line with its established conflict of interest policies.
After Proposition 14 was declared successful, the campaign supporting it called the measure one of the most important investments our state can make.
Over the past decade, California has made incredibly thoughtful and impactful investments in developing stem cell therapies and cures for diseases and conditions like diabetes, cancer, blindness, Parkinsons, paralysis and many more, wrote Robert and Danielle Klein, with the Californians for Stem Cell Research, Treatments and Cures campaign, in a statement. Now we know this progress and work to mitigate human suffering, restore health and improve the human condition will continue.
The measure will ultimately result in California taking on $7.8 billion dollars in debt, including interest.
See more here:
California's Stem Cell Agency Will Get A Funding Boost From Prop 14. Here's A Look At Its History. - Capital Public Radio News
- The Science Of Health: Are Spinal Cord Injuries Irreversible? Know Science Advances That Can Cure Them In The Future - ABP Live - October 16th, 2023
- Biden Weaponized Health Care on Abortion, Transgender, COVID-19 - Daily Signal - April 23rd, 2023
- Can This Company's Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval? - Marketscreener.com - November 17th, 2022
- BIOADAPTIVES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - November 17th, 2022
- With fewer inmates (and officers), Michigan closes another prison - Bridge Michigan - September 12th, 2022
- Testol 140 Review, Real Testol-140 Reviews Before and After Results - Dailyuw - September 12th, 2022
- Can California deliver on its zero-emission car goal? - Los Angeles Times - September 12th, 2022
- Researchers revive abandoned technique in effort to make artificial human eggs in a test tube - STAT - August 3rd, 2022
- 'Incredibly prejudicial': Why Sacramento courts have caged cells, and why that'll change - Walla Walla Union-Bulletin - August 3rd, 2022
- Ethical Issues in Stem Cell Research - PubMed Central (PMC) - December 22nd, 2021
- Dream Body Clinic Stem Cell Therapy Stem Cells HGH - December 22nd, 2021
- Stem cells | healthdirect - December 22nd, 2021
- Human Embryonic Stem Cells | The Embryo Project Encyclopedia - December 22nd, 2021
- Stem cells, through a religious lens Harvard Gazette - December 22nd, 2021
- Scientists identify 2nd HIV patient whose body rid itself of virus - National Herald - November 21st, 2021
- Need to streamline research on CRISPR gene-editing technology: Experts - Business Standard - November 21st, 2021
- Atrial Fibrillation Market Growth Driven by Technological Advancements in AFib Systems and Solutions and Rapidly Increasing Geriatric Population -... - November 21st, 2021
- Could Regenerative Biology Work in Humans? - Harvard Magazine - July 21st, 2021
- Alberta and NWT Bishops OK vaccination for COVID Grandin Media - Grandin Media - December 3rd, 2020
- The way prisoners flag guard abuse, inadequate health care and unsanitary conditions Is broken - injusticewatch.org - December 3rd, 2020
- From Roaches To Medical Emergencies, Illinois Inmates Say Theres Nobody That We Can Really Go To For Help - WBEZ - December 3rd, 2020
- Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS (ravulizumab) with Significantly Reduced Infusion... - November 20th, 2020
- Stem Cell Banking Market is Projected to Reach $6,956 million by 2023 | Leading key players are Cord Blood Registry, ViaCord, Cryo-Cell, China Cord... - November 19th, 2020
- Locked up during the Waupun COVID surge - Wisconsin Examiner - November 19th, 2020
- Panelists debate the implications and ethics of stem cell research - Johns Hopkins News-Letter - November 2nd, 2020
- Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's US Manufacturing Facility... - November 2nd, 2020
- Is the Pro-Life Movement on a Collision Course with the Coronavirus? - The Dispatch - November 2nd, 2020
- Will Trevor Lawrence stay at Clemson to avoid the Jets? - Yahoo! Voices - November 2nd, 2020
- Spurs' Becky Hammon honored with impressive San Antonio mural - Yahoo! Voices - November 2nd, 2020
- Total Student Enrollment of China New Higher Education Group Achieves Strong Organic Growth to a New Record High -- Total Number of Enrolled Students... - November 2nd, 2020
- Elis announces the acquisition of 3 laundries in Brazil - Yahoo Finance UK - November 2nd, 2020
- Stem Cell Banking Market is forecast to reach $6,956 million by 2023 | ViaCord,Cryo-Cell, China Cord Blood Corporation, Cryo-Save - The Daily... - October 2nd, 2020
- Those linked to stem cell board received more than $2.1 billion - Capitol Weekly - September 16th, 2020
- Patenting Stem Cell Inventions in India- What to Expect? - Lexology - September 13th, 2020
- Global Stem Cell Banking Market Is Projected To Witness Vigorous Expansion By 2026 - Kewaskum Statesman News Journal - September 13th, 2020
- How Close Are We To Making Babies from Bone Marrow? - Discover Magazine - August 12th, 2020
- India could bleed itself dry amidst covid-19 crisis owing to blood shortage - ETHealthworld.com - July 12th, 2020
- Court rules controversial stem cell research is legal - July 10th, 2020
- Legal Issues in Stem Cell Therapy in the U.S. - Inventus Law - June 19th, 2020
- Restoring vision to the blind - Science Magazine - May 22nd, 2020
- Death of a Survivor - The New Republic - May 4th, 2020
- Could Cannabis Be an Effective Treatment for COVID-19? - Lab Manager Magazine - April 29th, 2020
- The Republicans who were once so pro-life they fought over one woman on life support now want to sacrifice grandma for the economy - The Independent - April 29th, 2020
- Russia's Humanitarian Law Obligations to Civilians in Occupied Ukrainian Territories in the Time of COVID-19 - Just Security - April 29th, 2020
- Merck Boosts Commercial Viral Vector and Gene Therapy Manufacturing Capacity - PR Newswire UK - April 22nd, 2020
- Insights Into the $8.8 Billion Cell Therapy Industry, 2020-2027 - Rising Adoption of Regenerative Medicine, Introduction of Novel Platforms &... - March 17th, 2020
- The tragic life of Meredith Vieira - Nicki Swift - March 17th, 2020
- The 411 on Stem Cells: What They Are and Why It's Important to Be Educated - Legal Examiner - February 20th, 2020
- The Challenge of Bioethics to Decision-Making in the UK - Westminster Abbey - February 20th, 2020
- Penn announces seven 2020 Thouron Award winners - Penn: Office of University Communications - February 20th, 2020
- BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week - GlobeNewswire - January 7th, 2020
- Drugs, Biologics, and Regenerative Medicine in 2019: A Successful Year Ends with Promise of a More Challenging 2020 - JD Supra - December 21st, 2019
- Edited Transcript of MRKR.OQ earnings conference call or presentation 12-Nov-19 10:00pm GMT - Yahoo Finance - November 29th, 2019
- BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update - GlobeNewswire - November 19th, 2019
- What to Know in Washington: Trump Ally in Impeachment Spotlight - Bloomberg Government - November 19th, 2019
- Do transhumanists need their own bill of rights? - Quartz - October 27th, 2019
- Does Stem Cell Therapy Work For Back Pain? - Regenexx - October 8th, 2019
- The Ethical, Social & Legal Issues of Cloning Animals ... - October 8th, 2019
- An Overview of Stem Cell Research | The Center for ... - October 5th, 2019
- Ethical Issues in Stem Cell Research | Endocrine Reviews ... - October 2nd, 2019
- Embryo - Wikipedia - October 2nd, 2019
- Legal Issues in Stem Cell Therapy in the U.S. - Royse Law Firm - September 14th, 2019
- Research With Stem Cells | American Medical Association - May 23rd, 2019
- Practical Problems with Embryonic Stem Cells - usccb.org - March 17th, 2019
- Stem Cells For Dummies: The Controvery, Pros and Cons ... - March 6th, 2019
- Human cloning - Wikipedia - February 18th, 2019
- stem cell | Definition, Types, Uses, Research, & Facts ... - December 12th, 2018
- Timeline of major events in stem cell research policy ... - August 25th, 2018
- stem-cells | ETHICAL, LEGAL, AND SOCIAL ISSUES - July 29th, 2018
- The Legal and Ethical Issues of Cloning That Make it ... - October 11th, 2017
- 5 Ethical and Legal Issues | Cord Blood: Establishing a ... - September 21st, 2017
- FDA Grants Orphan Drug Status to Cellect's ApoGraft for Acute GvHD and Chronic GvHD - PR Newswire (press release) - September 5th, 2017
- Of cell phones and swords things Amarilloans should know about new state laws - Amarillo.com - September 1st, 2017
- Cellect Shares Will Be Traded From Next Week Exclusively on NASDAQ - PR Newswire (press release) - September 1st, 2017
- ICMR to release stem cell research guidelines soon - BSI bureau (press release) - September 1st, 2017
- ICMR's stem cell research guidelines soon to be released - ETHealthworld.com - August 31st, 2017
- Should your medical data be off the record? - The Irish Times - Irish Times - August 25th, 2017
- Combatting the spread of anti-vaccination sentiment - OUPblog (blog) - August 25th, 2017
- Embryonic stem cell - Wikipedia - August 24th, 2017
- How processing health data has become increasingly problematic - Irish Times - August 24th, 2017